Skip to main content
INVA logo

INVA · Innoviva, Inc. · Debt

Track INVA — free
$18.41 +0.01 (+0.05%) At close · Nov 19
Market Cap
$1.31B
Shares
71.08M
Volume · Nov 19 839.65K Avg daily vol (3M) 856.57K

Debt Profile

Completed filing coverage through Mar 21, 2022

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Noncurrent debt carrying amount 2026-09-30 USD 258,822,000 10-Q filed 2026-11-04
Operating lease liabilities 2026-09-30 USD 11,049,000 10-Q filed 2026-11-04
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 759,000
Noncurrent operating lease liabilities
USD 10,290,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

2.125% convertible senior notes due 2028

Note · Innoviva, Inc.

Reference: 2.125% convertible senior notes due 2028

Active
Original principal
USD 225,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 2.125% Reported 2022-03-21 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. AdditionalIssuance · 2022-03-18 Original principal USD 36,000,000 Exact source document Parent 8-K filing · 2022-03-21
    On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
    Issuer evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
    Supporting evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
  2. Issuance · 2022-03-07 Original principal USD 225,000,000 Exact source document Parent 8-K filing · 2022-03-21
    On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
    Issuer evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
    Supporting evidence: On March 18, 2022, Innoviva, Inc. (“Innoviva”) completed its offering of $36.0 million aggregate principal amount of its 2.125% convertible senior notes due 2028 (the “Additional Notes”). The Additional Notes were sold to Goldman Sachs & Co. LLC and Moelis & Company LLC (the “Initial Purchasers”) pursuant to the Initial Purchasers’ partial exercise of their option to purchase such notes, granted in connection with the previously disclosed offering of $225 million aggregate principal amount of Innoviva’s 2.125% convertible senior notes due 2028 (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which closed on March 7, 2022. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of March 7, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, as the Initial Notes, as described in the Company’s Current Report on [Form 8-K filed with the Securities and Exchange Commission on March 8, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) (the “Initial Form 8-K”). The information set forth in the [Initial Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000110465922031613/tm228653d1_8k.htm) is incorporated herein by reference.
Key facts CIK 1080014 CUSIP 45781M101 13F (30d) 299 filings 267 filers Visit website Investor relations